Cencora is scaling its third party logistics network across the United States and Europe as pharmaceutical supply chains face growing pressure to handle high value, temperature sensitive therapies. The company’s latest investments are designed to increase capacity, strengthen cold chain resilience and support manufacturers seeking integrated, end to end distribution solutions.

In Europe, Cencora is expanding its footprint through the addition of NextPharma Logistics, which operates across Germany, Austria and Switzerland. The move enhances its capabilities in regulated healthcare logistics, combining established expertise in serialization, compliance and temperature controlled storage with facilities built for refrigerated and deep frozen conditions. A new 3PL site in Italy, set to open in 2026, will join recent storage expansions in France, Spain and the United Kingdom to create a broader pan European platform. Cold chain strength is set to rise further with a new cryogenic equipped specialty unit in the Netherlands and added frozen and chilled capacity in France.

In the United States, momentum is similar. A new 500,000 square foot automated 3PL hub in Texas, expected to be operational in 2028, will become the company’s fifth major nationwide site. Cencora has already tripled cryogenic and ultra low temperature capacity to support advanced treatments such as cell and gene therapies, helping drug developers manage products from early clinical stages to commercial distribution.

The company, which delivers more than $300 billion in annual revenue and employs over 51,000 people, is positioning these investments to meet rising global demand for specialised pharmaceutical logistics. Expanded infrastructure and temperature flexibility across its network will allow Cencora to support manufacturers navigating increasingly complex supply requirements.

Access the full article to explore the implications for global pharmaceutical supply chains.